国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

交易中 08-21 10:40:00

16.570

-0.010

-0.06%

最高16.660	最低16.460	成交量115.00万
今开16.580	昨收16.580	日振幅1.21%
总市值517.15亿	流通市值222.34亿	总股本31.21亿
成交额1,904万	换手率0.09%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":16.57,"timestamp":1787279933613,"preClose":16.58,"halted":0,"volume":1150000,"delay":0,"changeRate":-0.0006031363088056702,"floatShares":1341810740,"shares":3121000000,"eps":2.6714631047248543,"marketStatus":"交易中","change":-0.01,"latestTime":"08-21 10:40:00","open":16.58,"high":16.66,"low":16.46,"amount":19043192,"amplitude":0.012063,"askPrice":16.57,"askSize":11200,"bidPrice":16.56,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":2.646438844873565,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1787284800000},"marketStatusCode":2,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":16.58,"dividendRate":0.048576,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.255503,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.2556,"impliedVolPercentile":0.3469},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"1138690175","title":"国药控股（01099）披露附属公司国药股份拟9,609.30万元转让国瑞药业12.06%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1138690175","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138690175?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:13","pubTimestamp":1787148794,"startTime":"0","endTime":"0","summary":"2026年8月19日，国药控股股份有限公司在港交所发布海外监管公告，披露其A股附属公司国药集团药业股份有限公司有关出售子公司股权及放弃优先购买权的交易细节。交易结构：国药股份拟以9,609.30万元的对价，向上海现代制药股份有限公司出售国药集团国瑞药业有限公司12.06%股权。股权变动：交易完成后，国药现代将持有国瑞药业51%股权，国药股份持股比例降至49%，国瑞药业自此不再纳入国药股份合并报表范围。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426014","title":"国药控股(01099)与国药集团、国药股份拟4.06亿元出售国瑞药业合计51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426014","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660426014?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:05","pubTimestamp":1787148331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股 发布公告，于2026年8月19日，本公司与国药集团、国药股份共同与国药现代订立股权转让协议，据此，本公司同意向国药现代出售本公司持有的目标公司国药集团国瑞药业有限公司30.13%股权，代价为人民币2.4亿元;国药股份同意向国药现代出售其持有的目标公司12.06%股权，代价为人民币9609.3万元;及国药集团同意向国药现代出售其持有的目标公司8.81%股权，代价为人民币7019.73万元。上述合计51%股权的转让代价合计为人民币4.06亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0097","LU1115378108.SGD","BK0250","600511","01099","BK0175","BK0082","BK1197","BK1500","LU0640798160.USD","BK0012","BK0188","BK1515","BK0028","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153430902","title":"国药控股（01099）4.06亿元转让国瑞药业51%股权 国瑞药业不再并表","url":"https://stock-news.laohu8.com/highlight/detail?id=1153430902","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153430902?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:01","pubTimestamp":1787148105,"startTime":"0","endTime":"0","summary":"2026年8月19日，国药控股股份有限公司公告称，公司与中国医药集团有限公司、国药集团药业股份有限公司及上海现代制药股份有限公司签署《股权转让协议》，拟向国药现代合计转让国药集团国瑞药业有限公司51%股权。交易对价合计406.3634百万元，折合约4.06亿元。公司表示，交易完成后，国瑞药业成为国药现代控股子公司，将有助于消除同业竞争、优化资产结构并推动医药制造板块协同。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165786518","title":"国药控股拟以2.4亿元出售国瑞药业30.13%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1165786518","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165786518?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:00","pubTimestamp":1787148010,"startTime":"0","endTime":"0","summary":"国药控股宣布，计划转让其所持有的国药集团国瑞药业有限公司30.13%股权，交易对价高达2.400731亿元人民币。\n这一重大资产处置举措，标志着这家医药巨头正在对其投资组合进行战略性调整。据悉，此次股权出售涉及国药控股在国瑞药业中的相当比例持股，交易金额精确至2.400731亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","LU0640798160.USD","BK1500","BK1515","01099","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197595679","title":"国药控股（01099）披露半年业绩：子公司国药股份上半年营收267.28亿元，归母净利8.80亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197595679","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197595679?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:11","pubTimestamp":1787137917,"startTime":"0","endTime":"0","summary":"8月19日，国药控股公布旗下A股子公司国药集团药业股份有限公司截至2026年6月30日的半年度报告。国药股份表示，下半年将继续推进“十五五”战略，深化业务结构优化，稳固北京市场基础，发力进口保税、SPD等增值服务，并加强精益化管理和数字化建设，以提升经营质量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447629","title":"国药控股(01099.HK)：国药股份(600511.SH)上半年归母净利润8.8亿元 同比减少7.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447629","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660447629?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:07","pubTimestamp":1787137633,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0640798160.USD","01099","LU1115378108.SGD","BK1500","BK1515","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182155569","title":"国药控股披露子公司国药股份2026年上半年主要财务数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1182155569","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182155569?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:05","pubTimestamp":1787137531,"startTime":"0","endTime":"0","summary":"2026年8月19日，国药控股股份有限公司公告了其附属公司国药集团药业股份有限公司截至2026年6月30日止六个月的主要未经审计财务数据。截至报告期末，国药股份总资产为360.40亿元，较上年度末的366.85亿元下降1.76%；归属于上市公司股东的净资产为188.10亿元，较上年度末的185.45亿元增长1.43%。扣除非经常性损益后，归属于上市公司股东的净利润为8.80亿元，同比下降5.55%。基本及稀释每股收益均为1.1660元，同比下降7.25%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165166847","title":"国药控股（01099）披露附属公司《2026年半年度报告》海外监管公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1165166847","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165166847?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:01","pubTimestamp":1787130118,"startTime":"0","endTime":"0","summary":"2026年8月19日，国药控股股份有限公司发布海外监管公告称，其附属公司中国医疗器械有限公司已于当日在中国货币网及上海清算所网站刊发《2026年半年度报告》，相关文件仅供投资者参阅。公告强调，香港交易及结算所有限公司及香港联合交易所有限公司对公告内容的准确性或完整性不承担任何责任。本次公告由国药控股股份有限公司董事长晋斌代表董事会发布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135153985","title":"国药控股(01099)披露国药器械2026年上半年主要业绩：营收364.92亿元同比增0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135153985","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135153985?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:51","pubTimestamp":1787129519,"startTime":"0","endTime":"0","summary":"本报讯 2026年8月19日，国药控股股份有限公司 发布公告，披露其附属公司中国医疗器械有限公司截至2026年6月30日止六个月的主要未经审计财务数据。报告期内，国药器械实现营业收入364.92亿元，较上年同期的363.63亿元增长0.36%。截至2026年6月30日，国药器械总资产为617.31亿元，较期初的573.02亿元增长7.73%；归属于母公司所有者权益合计为85.01亿元，较期初增加2.42%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446843","title":"国药控股(01099)：国药器械中期营业利润5.99亿元 同比减少12.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446843","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660446843?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:50","pubTimestamp":1787129409,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布国药器械截至2026年6月30日止六个月业绩，该公司取得营业收入364.92亿元(人民币，下同)，同比增加0.36%;营业利润5.99亿元，同比减少12.34%;归属于母公司所有者的综合收益2.87亿元，同比减少2.56%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640798160.USD","01099","BK1515","BK1197","LU1115378108.SGD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122915991","title":"国药控股(01099)更新董事会及五大专门委员会组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1122915991","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122915991?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:35","pubTimestamp":1787049342,"startTime":"0","endTime":"0","summary":"2026年8月18日，国药控股股份有限公司发布公告，披露最新董事会成员名单及其在五大专门委员会中的任职情况。公告显示，董事会成员共分为非执行董事、执行董事及独立非执行董事三类。董事会下设五个专门委员会，分别为：审核委员会、薪酬委员会、提名委员会、战略与投资委员会，以及法律合规与环境、社会及治理委员会。此次披露进一步明确了国药控股董事会及其专门委员会的职责分工，为公司治理结构提供了最新信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181710382","title":"国药控股（01099）调整董事会专门委员会成员 任命2026年8月18日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1181710382","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181710382?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:35","pubTimestamp":1787049339,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司8月18日公告，董事会通过调整部分专门委员会成员的决议，相关任命自2026年8月18日起生效。根据公告，执行董事杨秉华获委任为董事会战略与投资委员会委员。非执行董事祖敬、文德镛被委任为董事会审核委员会委员。非执行董事李莹被委任为董事会提名委员会委员。非执行董事邢永刚被委任为董事会法律合规与环境、社会及治理委员会委员。国药控股股份有限公司董事长晋斌在公告上签署日期为2026年8月18日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152614679","title":"国药控股（01099）转发国药一致2026年半年度业绩快报：营收36,266,356.60万元 同比下降1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152614679","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152614679?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:02","pubTimestamp":1786971768,"startTime":"0","endTime":"0","summary":"2026年8月17日，国药控股刊发海外监管公告，转发其A股及B股上市附属公司——国药集团一致药业股份有限公司于深圳证券交易所披露的《2026年半年度业绩快报》。国药一致2026年上半年实现营业总收入36,26,635.60万元，同比下降1.44%；营业利润83,443.04万元，同比下降9.94%；利润总额82,738.49万元，同比下降9.88%；归属于上市公司股东的净利润60,620.36万元，同比下降8.97%；扣除非经常性损益后的归属于上市公司股东净利润59,887.41万元，同比下降6.84%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116915082","title":"国药控股（01099）披露子公司国药一致2026年半年度业绩快报：营收362.66亿元，同比下降1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116915082","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116915082?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:02","pubTimestamp":1786971751,"startTime":"0","endTime":"0","summary":"2026年8月17日，国药控股股份有限公司公告旗下深圳证券交易所上市子公司国药集团一致药业股份有限公司截至2026年6月30日止六个月的主要未经审计财务数据。基本每股收益0.99元，同比下降9.17%；加权平均净资产收益率3.21%，同比下降0.49个百分点。分业务来看，分销板块实现营业收入2,653,900.00万元，同比下降0.91%；净利润46,000.00万元，同比下降4.56%。零售板块实现营业收入1,022,700.00万元，同比下降2.40%；净利润1,300.00万元，同比下降19.74%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660511438","title":"国药控股：2026年半年度净利润同比减少8.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660511438","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660511438?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:00","pubTimestamp":1786971600,"startTime":"0","endTime":"0","summary":"南财智讯8月17日电，国药控股（01099.HK）公告，国药集团一致药业股份有限公司（国药一致，000028.SZ/200028.SZ）披露2026年半年度业绩快报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843465027.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843465027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184788352","title":"国药一致2026年上半年归母净利润6.062亿元，同比下降8.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184788352","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184788352?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:59","pubTimestamp":1786971550,"startTime":"0","endTime":"0","summary":"国药一致（000028.SZ）公布2026年上半年业绩报告，归属于母公司股东的净利润为6.062亿元人民币，较去年同期下滑8.97%。母公司国药控股（01099.HK）旗下这一核心医药分销平台，上半年经营表现承压，盈利能力有所收窄。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0082","BK0188","BK0196","BK1197","LU0640798160.USD","01099","LU1115378108.SGD","BK0010","000028","BK1515","BK0175","BK1500","BK0185","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU2778985437.USD","BK1500","LU0348735423.USD","AGIX","KURE","LU0348827113.USD","01477","03933","01099","LU2328871848.SGD","AIPO","LU0417516571.SGD","LU0540923850.HKD","02268","02367","BK1191","02196","601066","LU0640798160.USD","QTOC","LU0348766576.USD","02228","KCE","LU0828237510.HKD","06160","LU1770034418.SGD","SG9999004311.SGD","VTHR","09688","LU0561508036.HKD","LU1303224171.USD","09926","LU0634319403.HKD","06821","LU2476274308.USD","CHAT","LU1719994722.HKD","LU0348825331.USD","LU0348784397.USD","LU2476274720.SGD","BK1197","LU0348783233.USD","LU0417516738.SGD","ARTY","01789","BK1515","01530","IE00B5MMRT66.SGD","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100858893","title":"财报前瞻｜国药控股本季度营收预计持稳，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1100858893","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100858893?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:28","pubTimestamp":1786667287,"startTime":"0","endTime":"0","summary":"国药控股将于2026年08月21日发布最新季度财报，市场关注其分销主业的需求修复与利润弹性。受限于可获取数据缺失，未形成明确一致预期与公司本季度指引中关于营收、毛利率、净利润或净利率、调整后每股收益的量化预测，故不展示相应数值；若公司在财报发布时给出更新指引，市场对利润端弹性的判断将及时修正。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜国药控股本季度营收预计持稳，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184256062","title":"国药控股（01099）将于8月21日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1184256062","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184256062?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:53","pubTimestamp":1786092796,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司董事会7日发布公告称，公司董事会会议拟于2026年8月21日（星期五）召开。会议议程包括审议及批准公司及其附属公司截至2026年6月30日止六个月之未经审计中期业绩。公告显示，会议通知由董事长晋斌签署并于2026年8月7日在上海发布。公司表示，香港交易及结算所有限公司及香港联合交易所有限公司对公告内容概不负责，并对其准确性或完整性不发表任何声明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139263610","title":"国药控股7月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1139263610","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139263610?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:40","pubTimestamp":1786005648,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司于2026年8月6日发布2026年7月股份变动月报。根据公告，报告期为2026年7月31日，显示公司注册股本和实际已发行股数均未发生变动。此外，公司确认已符合相关香港联交所《上市规则》所要求的公众持股量要求，股本结构在本月保持稳定。本次公告由公司秘书吴壹建签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":-0.0096},{"period":"1month","weight":-0.0427},{"period":"3month","weight":-0.0072},{"period":"6month","weight":-0.1695},{"period":"1year","weight":-0.116},{"period":"ytd","weight":-0.1037}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0271},{"period":"1year","weight":0.0212},{"period":"ytd","weight":0.0027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004652},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029404},{"month":3,"riseRate":0.470588,"avgChangeRate":0.00701},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016475},{"month":5,"riseRate":0.588235,"avgChangeRate":-0.009205},{"month":6,"riseRate":0.411765,"avgChangeRate":-0.006214},{"month":7,"riseRate":0.529412,"avgChangeRate":-0.008781},{"month":8,"riseRate":0.411765,"avgChangeRate":0.008696},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.01118},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042281},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.00729},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004119}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}